Internal investment planning continues pharmaceutical industryafter the approval of 53 investments in the amount of 519.28 million euros under the action “Reform of the system of return and compensation of costs for research and investment”, Greece 2.0 National Recovery and Resilience Plan.

These 53 projects meet all the requirements and conditions for participation, with 85% of them implemented by Greek companies. The above projects are part of the Greek pharmaceutical industry’s investment plan for a total of 1.2 billion euros over four years.

According to the related statement, these investments have a multiplier effect on the economy through the creation of added value, which remains and is reinvested in the country. In addition, these investments reduce Greece’s trade deficit, as it ensures that needs are met through domestic pharmaceutical production, while at the same time employment is increased through new permanent, skilled and well-paid jobs.

After the completion of the investment, the Greek pharmaceutical industry hopes that Greece will become a European “hub” of production, research and innovation, and the phase-out of drug imports from third countries such as China and Asia will be completed. Commenting on the approval of 53 investments under the Greece 2.0 National Recovery and Sustainability Plan, Theodoros Trifon, President of the Panhellenic Pharmaceutical Industry Association, said: “The Greek pharmaceutical industry is actively involved in efforts to rebuild the national economy.

With the help of three jointly competent ministries and in the context of compensation of compensation through productive investments in the sector, investments are made that bring multiplier benefits to society. In particular, they protect the health care system and pharmaceutical care, ensuring market adequacy and access of patients to any necessary treatment, reducing dependence on imports, and at the same time will lead to our country becoming a center of drug research and production in the wider Southeast region. Europe”.